Propofol
| Evidence Level: L2 | Predicted Indications: 5 |
Table of Contents
Propofol: From General Anesthesia and Sedation to Migraine Disorder
One-Sentence Summary
Propofol is an intravenous anesthetic that is marketed in India under 20 valid registrations. The TxGNN model predicts it may be effective for migraine disorder, supported by 3 clinical trials (one completed Phase 2/3 trial) and 20 publications, including several randomized trials and systematic reviews of low-dose propofol for acute migraine in the emergency department.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the India licence data compiled for this report (propofol is generally used as an intravenous anesthetic/sedative) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9969 |
| Evidence Level | L2 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Propofol is a positive allosteric modulator of the GABA-A receptor. Enhanced GABAergic inhibition may dampen trigeminovascular pain signalling and cortical hyperexcitability. Preclinical work also shows that propofol hemisuccinate suppresses cortical spreading depression, the proposed correlate of migraine aura.
The approved use of propofol (anesthesia and sedation) and the predicted use (abortive treatment of refractory migraine) share a central nervous system, inhibitory-neurotransmission mechanism. In practice, sub-anesthetic doses have been used for refractory migraine, mainly in the emergency department under monitored conditions. Note that the data compiled for this report do not include a formal mechanism-of-action entry, so this rationale rests on the literature and mechanistic analysis.
Other predicted indications are much weaker. Migraine with brainstem aura has only indirect, preclinical, and general-migraine evidence. Prinzmetal angina is linked only to case reports of coronary spasm during anesthesia, which is a possible safety signal and not a therapeutic rationale. Nephrogenic syndrome of inappropriate antidiuresis has no identifiable mechanistic link, and Tourette syndrome evidence concerns only sedation during deep brain stimulation surgery. These four were not pursued further.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01604785 | Phase 2/3 | Completed | 74 | Low-dose propofol as abortive therapy for pediatric migraine in the emergency department; full design (randomization, comparator) not confirmed in the available data |
| NCT02485418 | Not applicable | Completed | 40 | Low-dose propofol infusion as an abortive agent in pediatric migraine; evaluates efficacy, safe dosing limits, and duration of effect |
| NCT02492295 | Not applicable | Terminated | 12 | Low-dose propofol for severe refractory migraine in adult emergency department patients; early termination and tiny enrollment limit its value |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33070469 | 2021 | RCT (double-blind) | Emerg Med Australas | Propofol vs placebo for early resolution of acute migraine in adult ED patients (1-hour headache resolution) |
| 29456086 | 2018 | RCT | J Emerg Med | Low-dose propofol for pediatric migraine; potential efficacy with favorable side effects and shorter length of stay |
| 32705801 | 2020 | Pilot RCT | Emerg Med Australas | Procedural-sedation-dose IV propofol vs standard therapy for initial migraine management in the ED |
| 35402989 | 2022 | Double-blind RCT | Arch Acad Emerg Med | Propofol + granisetron vs propofol + metoclopramide for symptom control in acute migraine |
| 35573713 | 2022 | RCT | Arch Acad Emerg Med | Sumatriptan + propofol vs sumatriptan alone in acute migraine |
| 31621134 | 2020 | Systematic review | Acad Emerg Med | Safety and efficacy of propofol for acute migraine in the ED; evidence limited |
| 41321235 | 2026 | Guideline | Headache | 2025 American Headache Society update on parenteral treatments for acute migraine in the ED |
| 39364614 | 2024 | Systematic review / network analysis | Headache | Effectiveness of parenteral agents in reducing relapse after severe acute migraine |
| 27454834 | 2016 | Review | Expert Rev Neurother | Drug profile of sub-anesthetic propofol in super-refractory migraine |
| 10759925 | 2000 | Clinical report | Headache | Early report of unique effectiveness of IV propofol in intractable migraine at an outpatient headache center |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 136438 | Mct Rof Injection | Vial of 20 ml injection | Not stated |
| Registration No. 219642 | Troypofol Injection | Vial of 50 ml injection | Not stated |
| Registration No. 174042 | Propofol 1% Infusion | Bottle of 50 ml infusion | Not stated |
| Registration No. 176433 | Profol Spiva 10mg Injection | Vial of 50 ml injection | Not stated |
| Registration No. 194798 | Rapifol 10mg Infusion | Bottle of 50 ml infusion | Not stated |
These are 5 of 20 valid single-ingredient registrations; all are injectable or infusion forms.
Safety Considerations
- Contraindication signals from the knowledge graph (drug-disease associations in the model’s knowledge graph, not label text): epilepsy, hypotensive disorder, respiratory failure, intracranial arteriosclerosis, inherited lipid metabolism disorder, and familial hyperlipidemia.
- Drug interactions: 228 interactions were identified. Most listed are Moderate, including morphine, opium, ondansetron, granisetron, dolasetron, clarithromycin, levofloxacin, cisapride, famotidine, and loperamide. Metronidazole is rated Minor.
- Other safety signal: Case reports describe coronary spasm and unmasked vasospastic angina during propofol anesthesia, which warrants cardiovascular caution.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2/3 trial, several randomized trials, and multiple systematic reviews support low-dose propofol for acute migraine, and it is already marketed in India. However, trial sizes are small, the evidence is mostly in emergency department settings, and propofol requires monitored administration, so this is best treated as a research question and not a routine indication.
To proceed, the following is needed:
- Package insert warnings and contraindications for the India-registered products (currently unavailable and a blocking gap for safety screening)
- Detailed mechanism-of-action data from DrugBank
- Full design and results of NCT01604785 (randomization, blinding, comparator, outcomes)
- Larger, well-powered randomized trials with defined dosing and relapse outcomes
- A monitored-setting protocol (staff, equipment, hypotension and respiratory depression management) and screening for cardiovascular risk, epilepsy, and respiratory compromise
- An interaction-management plan for concomitant opioids and QT-prolonging antiemetics
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.